6th Annual Global Summit on
HEMATOLOGIC Malignancies

MARCH 13-17, 2019
FAIRMONT CHÂTEAU, WHISTLER
BRITISH COLUMBIA, CANADA

SUMMIT CHAIRS:

Steven Coutré, MD
Professor of Medicine
Stanford University Cancer Center
Stanford, CA

Joseph Mikhael, MD, MEd, FRCP, FACP
Professor, Applied Cancer Research and Drug Discovery
Translational Genomics Research Institute at City of Hope
Duarte, CA

Richard Stone, MD
Professor of Medicine
Director, Translational Research, Adult Leukemia Program
Dana-Farber Cancer Institute/
Harvard Medical School
Boston, MA

Andrew Zelenetz, MD, PhD
Medical Director, Quality Informatics
Memorial Sloan Kettering Cancer Center
New York, NY

For more information and to REGISTER visit:
FACULTY

Michael Andreef, MD, PhD
Professor of Medicine
University of Texas MD Anderson Cancer Center
Houston, TX

David Avigan, MD
Co-Director, Immunotherapy Institute
Beth Israel Deaconess Medical Center
Boston, MA

Veronika Bachanova, MD
Associate Professor of Medicine
University of Minnesota
Minneapolis, MN

Nizar Bahlis, MD
Associate Professor
University of Calgary
Calgary, Alberta

Connie Batlevi, MD, PhD
Assistant Attending Physician
Memorial Sloan Kettering Cancer Center
New York, NY

William Bensinger, MD
Director, Myeloma Program
Swedish Cancer Institute
Seattle, WA

Prithviraj Bose, MBBS
Associate Professor
University of Texas MD Anderson Cancer Center
Houston, TX

Jennifer Brown, MD, PhD
Director, Chronic Lymphocytic Leukemia Center
Associate Professor of Medicine
Harvard Medical School/Dana-Farber Cancer Institute
Boston, MA

Steven Coutre, MD CHAIR
Professor of Medicine
Stanford University Cancer Center
Stanford, CA

Alexey V. Danilov, MD, PhD
Associate Professor of Medicine
Oregon Health and Science University
Portland, OR

Sven de Vos, MD, PhD
Professor
David Geffen School of Medicine at UCLA
Los Angeles, CA

Courtney DiNardo, MD, MSCE
Assistant Professor
University of Texas MD Anderson Cancer Center
Houston, TX

Brian Hill, MD, PhD
Director, Lymphoid Malignancies Program
Taussig Cancer Institute
Cleveland, OH

Thomas Kipps, MD, PhD
Distinguished Professor of Medicine
UC San Diego Health, Moores Cancer Center
La Jolla, CA

John Kuruvilla, MD, FRCPC
Assistant Professor
University of Toronto
Toronto, Canada

Matthew Lunning, DO, FACP
Associate Professor
University of Nebraska
Omaha, NE

David Maloney, MD, PhD
Professor of Medicine
University of Washington/Fred Hutchinson Cancer Center
Seattle, WA

Thomas Martin, MD
Professor of Clinical Medicine
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Anthony Mato, MD, MSCE
Director, CLL Program
Memorial Sloan Kettering Cancer Center
New York, NY

Soheil Meshinchi, MD, PhD
Professor of Medicine
Fred Hutchinson Cancer Center
Seattle, WA

Joseph Mikhael, MD, MEd, FRCP, FACP CHAIR
Professor, Applied Cancer Research and Drug Discovery
Translational Genomics Research Institute at City of Hope
Duarte, CA

David Miklos, MD, PhD
Clinical Director of Cancer Cell Therapy
Associate Professor of Medicine
Stanford University
Stanford, CA

John Pagel, MD, PhD
Chief of Hematologic Malignancies
Swedish Cancer Institute
Seattle, WA

Krina Patel, MD
Assistant Professor
University of Texas MD Anderson Cancer Center
Houston, TX

Krish Patel, MD
Oncologist
Swedish Cancer Institute
Seattle, WA

Naveen Pemmaraju, MD
Associate Professor of Medicine
University of Texas MD Anderson Cancer Center
Houston, TX

Alexander Perl, MD
Associate Professor
University of Pennsylvania/Abramson Cancer Center
Philadelphia, PA

Tycel Phillips, MD
Associate Professor
University of Michigan Medicine
Ann Arbor, MI

Radhakrishnan Ramchandren, MD
Professor
Chief, Division of Hematology/Oncology
The University of Tennessee Graduate School of Medicine
Knoxville, TN

Farhad Ravandi-Kashani, MD
Professor of Medicine
Chief, Section of Developmental Therapeutics
University of Texas MD Anderson Cancer Center
Houston, TX

Sarah Rutherford, MD
Assistant Professor
Weill Cornell Medicine
New York, NY

Charles Schiffer, MD
Professor of Medicine
Barbara Ann Karmanos Cancer Institute
Detroit, MI

Stephen Schuster, MD
Professor of Medicine
University of Pennsylvania
Philadelphia, PA

Nina Shah, MD
Associate Professor
University of California San Francisco
San Francisco, CA

Jeff Sharman, MD
Medical Director, Hematology Research
The US Oncology Network
Eugene, OR

Edward Stadtmauer, MD
Section Chief, Hematologic Malignancies, Roseman, Tarte, Harrow, and Shaffer Families’ President’s Distinguished Professor
University of Pennsylvania/Abramson Cancer Center
Philadelphia, PA

Deborah Stephens, DO
Assistant Professor
University of Utah
Salt Lake City, UT

Richard Stone, MD CHAIR
Professor of Medicine
Director, Translational Research, Adult Leukemia Program
Dana-Farber Cancer Institute/Harvard Medical School
Boston, MA

Koichi Takahashi, MD
Assistant Professor
University of Texas MD Anderson Cancer Center
Houston, TX

Steven Treon, MD
Director, Bing Center for Waldenström’s Macroglobulinemia
Dana-Farber Cancer Institute
Boston, MA

Ravi Vij, MD, MBA
Professor of Medicine
Washington University School of Medicine in St. Louis
St. Louis, MO

Roland Walter, MD
Associate Member
Fred Hutchinson Cancer Research Center
Seattle, WA

Eunice Wang, MD
Chief, Leukemia Service
Roswell Park Cancer Institute
Buffalo, NY

Jason Westin, MD, MS, FACP
Lead, Aggressive Lymphoma Department of Lymphoma & Myeloma
University of Texas MD Anderson Cancer Center
Houston, TX

Adrian Wiestner, MD, PhD
Senior Investigator
NIH National Heart, Lung, and Blood Institute
Bethesda, MD

Andrew Zelenetz, MD, PhD CHAIR
Medical Director, Quality Informatics
Memorial Sloan Kettering Cancer Center
New York, NY

Jeffrey Zonder, MD
Professor of Oncology
Barbara Ann Karmanos Cancer Institute
Detroit, MI
Wednesday, March 13, 2019

Setting the Stage

Session Chair: Charles Schifer

5:00 PM Welcome and Introductions
5:15 PM Targeting the Mitochondria in B-cell Malignancies
Alexey Danilov
5:30 PM Can We Finally Start Sub-setting DLBCL in 2019?
Sven de Vos
5:45 PM How Do We Get to the Next Inflection Point in MM?
Thomas Martin
6:00 PM BREAK
6:30 PM FLT3 Madness: Anarchy in Clinical Trials
Charles Schiffer
6:45 PM What’s New in AML: How to Develop New Drugs in AML
Alexander Perl
7:00 PM How to Limit the Impact of CLL on Patients’ Lives
Thomas Kipps
7:15 PM PANEL DISCUSSION
8:00 PM ADJOURN TO WELCOME RECEPTION

Thursday, March 14, 2019

Chronic Lymphocytic Leukemia

Session Chair: Steven Coutre

7:00 AM CLL Combinations: Is the Whole Greater than the Sum of the Parts?
Anthony Mato
7:15 AM How Can We Overcome the Immunosuppressive Microenvironment in CLL?
Veronika Bachanova
7:30 AM MRD in CLL: How Deep Should We Go?
Anthony Mato*
7:45 AM DISCUSSION
8:00 AM Overcoming Primary and Acquired Resistance to BTKi in WM
Steven Treon
8:15 AM Influence of BTK Inhibitors on Immune Function
Adrian Wiestner
8:30 AM Updated Results: Next-generation BTKi
John Pagel
8:45 AM What are the Next Steps for Ibrutinib in CLL?
Jennifer Brown*
9:00 AM DISCUSSION
9:30 AM BREAK
9:45 AM Update on Murano Data (R/R vs. BR)*
Steven Coutre
10:00 AM Venetoclax: Impact of Early Intervention in CLL
Deborah Stephens
10:15 AM Emerging Data on PI3K Resistance in CLL
Jennifer Brown
10:30 AM PANEL DISCUSSION

Biotech Showcases

Session Chair: John Pagel

11:00 AM Vacabrutinib (SNS-062): A Potent, Reversible Non-covalent Inhibitor of BTK (Sunesis Biotech Showcase)
Jennifer Brown
11:10 AM Zanubrutinib (BGB-3111): A Potent, Irreversible Covalent Inhibitor of BTK (BeiGene Biotech Showcase)
Bill Novotny
11:20 AM LOXO-305: The Next-generation BTK Inhibitor Overcomes BTK C481 Mutations (LOXO Biotech Showcase)
John Pagel
11:30 AM Targeted Degradation of BTK as a Novel Therapeutic Strategy in B-cell Malignancies
Nancy Pryer
11:40 AM Duvelisib: PI3K-δ (delta) and PI3K-γ (gamma) Inhibitor for the Treatment of R/R CLL/SLL and FL after Two Prior Lines of Therapy
Alexey Danilov
11:50 AM The treatment of Refractory NHL with Hu5F9-G4, a Novel Inhibitor of the Macrophage “Don’t Eat Me” Signal, CD47 (Forty-Seven Biotech Showcase)
Chris Takimoto
12:00 PM ADVISORY BOARDS

Debating Technology: Is There a Role for Chemotherapy in CLL?

Session Chair: Jennifer Brown

5:00 PM Chemo-free Options: The Future of CLL Treatment
Thomas Kipps
5:10 PM Chemotherapy is Not Dead in CLL
Andrew Zelenetz*
5:20 PM PANEL DISCUSSION: Jennifer Brown, Steven Coutre, and John Pagel

Lymphomas

Session Chair: Sven de Vos

6:00 PM Ibrutinib and Venetoclax in Frontline DLBCL
Sven de Vos
6:15 PM Polatuzumab in DLBCL
Jeff Sharman
6:30 PM The Role of Non-chemotherapy Options in MCL
Tycel Phillips
6:45 PM Approach to Patients with FL in Early Transformation
Brian Hill
7:00 PM Development of Rational Combinations with PI3K in Heme Malignancies
Matthew Lunning
7:15 PM Can Bispecific CAR-T Overcome Challenges with Traditional CAR-T Therapy in DLBCL?
David Miklos
7:30 PM Challenges in Clinical Trial Design for CAR-T in R/R DLBCL
Jason Westin
7:45 PM PANEL DISCUSSION
8:30 PM ADJOURN TO POSTER RECEPTION

*Indicates awaiting confirmation
**Friday, March 15, 2019**

**Multiple Myeloma**

*Session Chair: Joseph Mikhael*

- **7:00 AM** How Many Drugs Do We Need in First-line Myeloma?  
  Nina Shah

- **7:15 AM** What’s Next for CAR-T in MM?  
  Edward Stadtmauer

- **7:30 AM** Ixazomib Maintenance in Newly Diagnosed Multiple Myeloma  
  Ravi Vij

- **7:45 AM** DISCUSSION

- **8:15 AM** Role of Daratumumab in Frontline Multiple Myeloma  
  Thomas Martin*

- **8:30 AM** Understanding Immune Resistance to Daratumumab in Myeloma  
  Nizar Bahlis

- **8:45 AM** What Role will Isatuximab Play in Multiple Myeloma?  
  Joseph Mikhael

- **9:00 AM** What is Next with CD38 Antibodies?  
  Krina Patel

- **9:15 AM** DISCUSSION

- **9:45 AM** BREAK

- **10:00 AM** Will Venetoclax also be a Multiple Myeloma Drug?  
  Joseph Mikhael

- **10:15 AM** Status of Anti-fibril Therapy (Monoclonal Antibodies) in AL Amyloidosis  
  Jeffrey Zonder

- **10:30 AM** PANEL DISCUSSION

**Biotech Showcases**

*Session Chair: Andrew Zelenetz*

- **10:50 AM** Elzonris: A Novel Targeted Therapy Directed to the IL-3R (Stemline Biotech Showcase)  
  Naveen Pemmaraju

- **11:00 AM** HDP-101: BCMA-ATAC for Multiple Myeloma  
  Heidelberg Pharma Speaker

- **11:10 AM** Advancing the Science of the TGF Beta Superfamily  
  Ravi Kumar

- **11:20 AM** ME-401 for the Treatment of R/R B Cell Malignancies  
  Andrew Zelenetz

- **11:30 AM** PANEL DISCUSSION

- **12:00 PM** ADVISORY BOARDS

**Debating Technology: Future Role of T-cell Engagers (CAR-T vs. Bispecifics)**

*Session Chair: Steven Coutré*

- **5:00 PM** CAR-T: The Technology of the Future  
  Edward Stadtmauer*

- **5:10 PM** Bi/Ti-specific Antibodies: The Optimal Way to Engage T-cells  
  Farhad Ravandi-Kashani

- **5:20 PM** PANEL DISCUSSION: Thomas Martin, David Miklos, Stephen Schuster, Nina Shah, and Andrew Zelenetz

**Acute Myeloid Leukemia**

*Session Chair: Richard Stone*

- **6:00 PM** Understanding the Biology of Hereditary AML  
  Courtney DiNardo

- **6:15 PM** Is the Age of 7+3 Coming to an End?  
  Eunice Wang

- **6:30 PM** Novel Agents: Beyond JAK Inhibition in Myelofibrosis  
  Prithviraj Bose

- **6:45 PM** Personalized Cancer Vaccines in Heme Malignancies  
  David Avigan

- **7:00 PM** Single Cell Genomic Analysis in AML  
  Koichi Takahashi

- **7:15 PM** BCL2 Inhibition in AML: The New Standard of Care?  
  Michael Andreff

- **7:30 PM** Venetoclax-based Existing and Upcoming Combinations  
  Courtney DiNardo

- **7:45 PM** Increasing Remissions in BPDCN with IL-3 Receptor Targeting and Beyond  
  Naveen Pemmaraju

- **8:00 PM** Patient Case in 2023: The Future of Treating AML  
  John Eckardt Koichi Takahashi

- **8:15 PM** PANEL DISCUSSION

- **8:30 PM** ADJOURN TO RECEPTION

**Saturday, March 16, 2019**

**Emerging Trends in Lymphoma and CLL**

*Session Chair: Andrew Zelenetz*

- **7:00 AM** HCK Inhibition in MYD88 Diseases  
  Steven Treon

- **7:15 AM** Novel Targeted Strategies: The Nuclear Pore and Beyond  
  Sarah Rutherford

- **7:30 AM** Durability of CAR-T Cell Remissions in Refractory B-cell Lymphomas: How Many People Can We Save and for How Long?  
  Stephen Schuster

- **7:45 AM** Armored CAR-T Cells in R/R NHL and CLL Including Richter’s Transformation  
  Connie Batlevi

- **8:00 AM** DISCUSSION

- **8:30 AM** Role of PD-1 and PD-L1 Therapy in Hodgkin’s Lymphoma  
  John Kuruvilla

- **8:45 AM** Incorporating Novel Therapeutics in Hodgkin’s Lymphoma  
  Rod Ramchandren

- **9:00 AM** Emerging Data on Bispecific Antibodies in Lymphoma  
  Krish Patel

- **9:15 AM** Emerging Role of ADCs in Combination with Chemotherapy for the Treatment of PTCL  
  Andrew Zelenetz*

- **9:30 AM** PANEL DISCUSSION

- **10:30 AM** BREAK

*Indicates awaiting confirmation
Biotech Showcases

*Session Chair: William Bensinger*

10:50 AM Biotech Showcase: Syk: Can it Rise from the Dead?  
Jeff Sharman

11:00 AM Fostamatinib: Syk Inhibition for the Treatment of ITP (Rigel Pharmaceuticals Biotech Showcase)  
Aaron Sheppard

11:10 AM Biotech Showcase: Curis Pipeline Update  
Robert Martell

11:20 AM PANEL DISCUSSION

12:00 PM ADVISORY BOARDS

Debating Technology: Utilizing Current CAR-T Therapy vs. Optimizing Future CARs

*Session Chair: David Maloney*

5:00 PM Finding a Role for Current CAR-T Technology  
William Bensinger

5:10 PM Necessity of Optimizing CAR-T Technology  
Nina Shah

5:20 PM PANEL DISCUSSION: Thomas Kipps, Joseph Mikhail, David Miklos, Stephen Schuster, and Edward Stadtmauer

Emerging Trends in Hematologic Malignancies

*Session Chair: Eunice Wang*

6:00 PM Feasibility of CAR-T Therapy for R/R DLBCL Patients in the Real World  
Brian Hill

6:15 PM Update on CAR-T Therapy for Lymphoma: Long-term Durability and Prospects for the Future  
David Maloney

6:30 PM Armored Monoclonal Antibodies in AML  
Roland Walter

6:45 PM Identifying Immunogenic Targets in AML  
Sohail Meshinchi

7:00 PM T-cell Based Therapies in AML  
Richard Stone

7:15 PM DISCUSSION

7:30 PM Role of FLT3 Post-transplant in AML  
Alexander Perl*

7:45 PM Future Roles of FLT3 Inhibition as Single-agent and Combination Therapy in AML  
Eunice Wang

8:15 PM Treatment Sequencing in Patients with R/R MM after Daratumumab  
Ravi Vij

8:30 PM Where is Selinexor Going to Fit in the Multiple Myeloma Landscape?  
Nizar Bahlis

8:45 PM PANEL DISCUSSION

9:15 PM ADJOURN

Sunday, March 17, 2019

6:00 AM BREAKFAST

Oral Abstracts

7:00 AM RNA and Flow-based Immune Assessments in Azacitidine and Nivolumab-treated Relapse/Refractory Acute Myeloid Leukemia (AML) Patients: A Subset Analysis of a Phase 2 Study  
Hussein Abbas

7:10 AM Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas  
Elise Chong

7:20 AM Rapid Hematologic and Organ Responses with Daratumumab, Bortezomib and Dexamethasone in Patients with Primary Refractory AL Amyloidosis  
Sarah Lee

7:30 AM Adaptive NK Cells are Expanded by NKG2C-agonist Antibodies but Exhibit Functional Exhaustion  
Aimee Merino

7:40 AM Characteristics and Outcomes of Ibrutinib-associated Musculoskeletal Toxicities in CLL Patients  
Joanna Rhodes

7:50 AM A Phase I/II Trial of Intravenous Azacitidine for Acute GVHD Prophylaxis in Patients Undergoing Matched Unrelated Stem Cell Transplantation: Phase II Results  
Mark Schroeder

8:00 AM Phase I/I Study of Umbralisib (TGR-1202) in Combination with Ubituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter’s Transformation  
Mazyar Shadman

8:10 AM PANEL DISCUSSION

8:30 AM ADJOURN

*Indicates awaiting confirmation